Jazeta Novum (Sitagliptin Phosphate Monohydrate)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, sitagliptin enhances glucose‑dependent insulin secretion and suppresses glucagon release, leading to lower blood glucose levels after meals and during fasting.

The dose of Jazeta Novum is individualized by the prescribing healthcare professional based on the patient’s renal function, glycaemic targets, and concomitant therapies. The prescriber determines the appropriate strength, frequency, and any necessary dose adjustments.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Jazeta Novum product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of hypoglycaemia because its glucose‑dependent mechanism requires elevated blood glucose to stimulate insulin. Relative to other DPP‑4 inhibitors, efficacy and safety are broadly comparable; choice often depends on formulation, cost, and patient‑specific factors.

Jazeta Novum should be stored at ambient temperature, below 25 °C, in its original blister pack or container. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Jazeta Novum is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not alter the regimen without medical advice.

The most serious adverse events reported with sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and, when combined with insulin or sulfonylureas, significant hypoglycaemia. Patients should be educated to seek immediate medical care if they experience persistent abdominal pain, rash, swelling, or symptoms of low blood sugar.

Jazeta Novum is contraindicated in individuals with a known hypersensitivity to sitagliptin or any excipients in the tablet. It should be used with caution, or avoided, in patients with severe renal impairment, a history of pancreatitis, or those taking medications that may cause dangerous hypoglycaemia without appropriate monitoring.